191 results
Page 4 of 10
8-K
EX-10.1
a9jma9p kjyw1epb
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-4.1
rrxdnrvlghpry3kaxpyi
8 Apr 21
Entry into a Material Definitive Agreement
4:29pm
8-K
EX-10.1
vdt05 ycup4cmgk5oil
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
8-K/A
EX-99.4
sbib4owp
5 Apr 21
Financial Statements and Exhibits
4:11pm
8-K
EX-99.1
grh0jf
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
EX-1.1
8xpxj9ruai p1y
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
424B5
yu1tqt12l
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
gk309yybpsafnaum
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
wh25 lv1m4uo42q5wuh
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K/A
EX-99.1
cvq breviu116sq
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.2
mxenz5sx9u4 pkc411o
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.3
zdisx6wbw2 kz5f
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
EX-99.1
ig2avwcr2pab x77hvl
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-10.3
oil2 0ntxbhcpgz05
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
yb96 fgegasncjx34u
28 Aug 20
Prospectus supplement
4:31pm